Publikationen:
Zeisig B., Garcia-Cuellar M.-P., Winkler T., and Slany R. (2002) The oncoprotein MLL-ENL disturbs hematopoietic lineage determination and transforms a biphenotypic lymphoid/myeloid cell. Oncogene: in revision
Zeisig B., Schreiner S., Garcia-Cuellar M.-P., Birke M., and Slany R. (2002) Transcriptional activation is a key function encoded by MLL fusion partners. Leukemia: accepted
Strehl S., Borkhardt A., Slany R., Fuchs U., König M., and Haas O. (2002) The human LASP1 gene is fused to MLL in an acute myeloid leukemia with t(11;17)(q23;q21). Oncogene: in press
Birke M., Schreiner S., Garcia-Cuellar M-P., Mahr K., Tigemeyer F., and Slany R. (2002) The MT-domain of the proto-oncoprotein MLL binds to CpG containing DNA and discriminates against methylation. Nucleic Acids Res.:30 (4), 958-965
Schreiner S., Birke M., Garcia-Cuellar M-P., Zilles O., Greil J., and Slany R. (2001) MLL-ENL causes a reversible and myc-dependent block of myelomonocytic cell differentiation. Cancer Research: 61, 6480-6486
Fuchs U., Rehkamp G., Haas O.A., Slany R., König M., Bojesen S., Bohle R.M., Damm-Welk C., Ludwig W-D., Harbott J., and Borkhardt A. (2001) The human formin-binding protein 17 (FBP17) interacts with sorting nexin, SNX2, and is an MLL-fusion partner in acute myelogeneous leukemia. Proc. Natl. Acad. Sci.: 98, 8756-8761
Garcia-Cuellar M.P., Zilles O., Schreiner S., Birke M., Winkler T.H., and Slany R.K. (2001) The ENL moiety of the childhood leukemia-associated MLL-ENL oncoprotein recruits human Polycomb 3. Oncogene: 20, 411-419
Garcia-Cuellar M.P., Schreiner S., Birke M., Hamacher M., Fey G.H., and Slany R. K. (2000) ENL, the MLL fusion partner in t(11;19) binds to the Abl interactor protein ABI1 that is fused to MLL in t(10;11). Oncogene: 19, 1744-1751
Schreiner S., Garcia-Cuellar M.P., Fey G.H., and Slany R.K. (1999) The leukemogenic fusion of MLL with ENL creates a novel transcriptional transactivator. Leukemia: 13, 1525-1533
Cui X., DeVivo I, Slany R., Miyamoto A., Firestein R., and Cleary M.L. (1998) Association of SET domain and myotubularin-related proteins modulates growth control. Nature Gen.: 18: 331-337
Slany R.K., Lavau C., and Cleary M.L.. (1998) The Oncogenic Capacity of HRX-ENL Requires the Transcriptional Transactivation Activity of ENL and the DNA Binding Motifs of HRX. Mol. Cell. Biol.: 18:122-129
Lavau C., Szilvassy S. J., Slany R. K. and Cleary M. L. (1997) Transformation of a Myelomonocytic Precursor by Retrovirally-Transduced HRX-ENL: EMBO J 16:4226-4237
Butler L.H., Slany R.K., Cui X., Cleary M.L. and Mason D.Y. (1997) The HRX Proto-oncogene Product is Widely Expressed in Human Tissues and Localises to Nuclear Structures. Blood, 89:3361-3370